• Abionyx Pharma signed a research partnership with Lille University Hospital to explore CER-001 in severe burn patients at high risk of sepsis.
• The program will examine biological changes linked to sepsis in burn and intensive care patients to guide potential clinical development.
• Research is planned rather than reporting completed results; findings could support expanding CER-001 development beyond sepsis to broader severe inflammatory conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abionyx Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103333309) on November 04, 2026, and is solely responsible for the information contained therein.